OnKure Therapeutics Raises $150 Million to Advance PI3Kα Pan-Mutant Inhibitors for Breast Cancer and Vascular Anomalies.

OnKure Therapeutics has raised $150 million in a private placement led by Access Biotechnology. The funds will support the advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies. The company plans to file INDs for each program in 1H 2027. Liam Ratcliffe has joined OnKure's Board of Directors. The financing will also fund preclinical and clinical development, working capital, and general corporate purposes.